Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01GuruFocus · 20 hr ago
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancersGuruFocus · Jul 27, 2026Edify Acquisition Corp. operates without any substantial business activities of its own. Its core objective is to achieve a business combination, such as a merger, asset acquisition, stock exchange, share purchase, or corporate reorganization, with one or more other entities. The company was founded in 2020 and is based in New York, New York.